TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05821569

Intervention type: OTHER
Intervention: Standard approach
Description: Adoption of standard approach (derived by Unicef guidelines) to breastfeed

Intervention type: OTHER
Intervention: Biological nurturing
Description: Adoption of biological nurturing approach to breastfeed
Study: NCT05171777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
Study: NCT04852055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Video
Description: Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
Study: NCT06101355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home Based Exercise Group
Description: Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
Study: NCT05265104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF with stainless steel crown
Description: Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser application with stainless steel crown
Description: Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown only
Description: the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
Study: NCT05822960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: far-infrared radiation
Description: far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
Study: NCT05841953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation
Description: Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
Study: NCT04989660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% aqueous phenol
Description: 1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
Study: NCT05645276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK129 IV infusion
Description: AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
Study: NCT05408052

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural (DPE)
Description: Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart Epidural
Description: The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance.
Study: NCT06066190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery
Description: Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
Study: NCT06102928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined therapy of anlotinib and aumolertinib
Description: Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
Study: NCT05307523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enriched Play Environment with Partial Body Weight Support Harness
Description: A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Play Environment without Partial Body Weight Support Harness
Description: Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
Study: NCT05298163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol capsules
Description: Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
Study: NCT06156462

Intervention type: DEVICE
Intervention: ResAppDx v.20
Description: Software device measuring cough sounds to aid diagnosis of respiratory diseases

Intervention type: DEVICE
Intervention: ResAppDx v.20
Description: Software device measuring cough sounds to aid diagnosis of respiratory diseases
Study: NCT05044351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam LX
Description: See arm description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery without NIRAF assistance
Description: Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
Study: NCT04914195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
Study: NCT06239701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA+Fitbit Intervention
Description: 1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: 1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls.
Study: NCT06380556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Description: The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
Study: NCT05094882

Intervention type: PROCEDURE
Intervention: pulmonary lobectomy
Description: resection of lung lobe

Intervention type: PROCEDURE
Intervention: pulmonary lobectomy
Description: resection of lung lobe

Intervention type: PROCEDURE
Intervention: pulmonary lobectomy
Description: resection of lung lobe

Intervention type: PROCEDURE
Intervention: pulmonary lobectomy
Description: resection of lung lobe

Intervention type: PROCEDURE
Intervention: pulmonary lobectomy
Description: resection of lung lobe
Study: NCT04641585

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patients affected by Brugada Syndrome 1
Description: ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients affected by Brugada Syndrome 1
Description: ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
Study: NCT06501833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+ KIDS PROGRAM
Description: The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REGULAR TRAINING
Description: The control group will be continuing their regular training
Study: NCT06342466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3mg/m2 sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4mg per day taken orally on 1-21 of repeated 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg-40mg weekly
Study: NCT04783480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Birthly
Description: Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Subjects will participate in childbirth education at their own discretion.
Study: NCT05965505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT-1003
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study: NCT05738668

Intervention type: OTHER
Intervention: Description of clinical characteristic
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study.
Study: NCT05157984

Intervention type: PROCEDURE
Intervention: ZPOEM
Description: Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)

Intervention type: PROCEDURE
Intervention: ZPOEM
Description: Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
Study: NCT06244472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experiment 1: visual and auditory attention task
Description: We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experiment 2: language production and rest tasks
Description: We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experiment 3: visuo-motor task
Description: We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experiment 4: brain activity at rest
Description: We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
Study: NCT06233981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
Description: All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
Study: NCT05842434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Felix
Description: Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
Study: NCT04177004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT05948449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin, Cadonilimab
Description: 3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
Study: NCT04177004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FTBI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FTBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goat Milk
Description: Given human lysozyme goat milk PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Given PO